The fragility index of randomized controlled trials in advanced/metastatic renal cell cancer
Not all RCTs associated with a/mRCC are as statistically robust as previously considered and should therefore be construed carefully. We suggest that additional reporting of FI in urological RCTs as a supplement to the P-value to assist readers in concluding reliably by considering the fragility of the outcomes.
Authors
- Haotian Wei (ORCID: https://orcid.org/0000-0001-9595-5931)
- Jiacheng Jin (ORCID: https://orcid.org/0000-0003-3854-4460)
- Jianbo Wang (ORCID: https://orcid.org/0000-0002-2667-3946)
- Yingwei Bi
- Liang Zhu (ORCID: https://orcid.org/0000-0002-8202-0413)
- Rui Wang (ORCID: https://orcid.org/0009-0006-0589-2062)
- Yuxin Liu (ORCID: https://orcid.org/0009-0005-3597-706X)
- Z. Zhai
- Kewen Qu
- Qing Ma (ORCID: https://orcid.org/0009-0007-3505-688X)
Institutions
- Dalian Medical University (CN)
- Second Hospital of Tianjin Medical University (CN)
- First Affiliated Hospital of Dalian Medical University (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Urologic Oncology Seminars and Original Investigations
- Published
- 2025-03-29
- DOI
- https://doi.org/10.1016/j.urolonc.2025.03.003
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China